Analysts polled by Capital IQ expected $0.51.

Net sales for the quarter ended March 31 was $3.86 billion, up from $3.39 billion a year earlier.

Analysts surveyed by Capital IQ expected $3.68 billion.

For Q2, the life sciences company expects adjusted earnings of $0.57 to $0.59 per share on revenue up 10.5% to 12.5%. Analysts polled by Capital IQ expect adjusted earnings of $0.56 per share on revenue of $3.93 billion.

For full-year 2024, the company expects adjusted earnings of $2.29 to $2.34 per share on revenue up 11% to 13%. Analysts polled by Capital IQ expect adjusted earnings of $2.25 per share on revenue of $15.58 billion.

Shares of the company were up more than 4% in recent Wednesday premarket activity.

Price: 71.90, Change: +2.91, Percent Change: +4.22

http://www.mtnewswires.com
Copyright © 2024 MT Newswires. All rights reserved. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.